Clinical Trials | November 10, 2025
Relmada gains FDA backing for two registrational trials and reports 92% response with NDV-01 in bladder Cancer
Relmada expects to initiate its Phase 3 program in the first half of 2026
Relmada expects to initiate its Phase 3 program in the first half of 2026
Bayer remains a key partner in Ginkgo Bioworks’ growing agricultural biologicals platform
From material selection to cooling tower management, every small decision affects long-term equipment reliability
Upon completion, Kimberly-Clark shareholders are expected to own about 54% of the combined entity, while Kenvue shareholders will hold the remaining 46%
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
Walmart, with nearly 4,600 pharmacies nationwide, will serve as the first in-store pickup pharmacy for LillyDirect's self-pay single-dose vials
The antibody was designed and developed at Abzena’s Cambridge, UK,
Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile
_256_384.jpg)
Tirzepatide is a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
